1. Home
  2. TREE vs DSGN Comparison

TREE vs DSGN Comparison

Compare TREE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LendingTree Inc.

TREE

LendingTree Inc.

HOLD

Current Price

$38.52

Market Cap

693.0M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

BUY

Current Price

$10.05

Market Cap

579.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
TREE
DSGN
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
693.0M
579.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TREE
DSGN
Price
$38.52
$10.05
Analyst Decision
Strong Buy
Buy
Analyst Count
5
3
Target Price
$75.00
$15.00
AVG Volume (30 Days)
405.9K
288.8K
Earning Date
03-02-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.04
N/A
Revenue
$1,059,158,000.00
N/A
Revenue This Year
$22.86
N/A
Revenue Next Year
$7.32
N/A
P/E Ratio
$40.67
N/A
Revenue Growth
37.01
N/A
52 Week Low
$33.50
$2.60
52 Week High
$77.35
$10.97

Technical Indicators

Market Signals
Indicator
TREE
DSGN
Relative Strength Index (RSI) 27.97 51.02
Support Level $42.86 $9.54
Resistance Level $48.98 $10.59
Average True Range (ATR) 3.83 0.63
MACD -1.93 -0.05
Stochastic Oscillator 2.36 35.47

Price Performance

Historical Comparison
TREE
DSGN

About TREE LendingTree Inc.

LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: